Zosano Pharma Corp Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2022-06-03: Form 8-K; Period of report 2022-06-02; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2022-06-02: Form 8-K; Period of report 2022-05-26; Description 1.02 Termination of a Material Definitive Agreement; 1.03 Bankruptcy or Receivership; 8.01 Other Events; Details 1.02.
- 2022-05-18: Form 8-K; Period of report 2022-05-16; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2022-05-13: Form 8-K; Period of report 2022-05-10; Description 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2022-06-03 | 8-K | 2022-06-02 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On June 2, 2022, Zosano Pharma Corporation (the “Company”) received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that as a result of the Company’s June 1, 2022 filing for protection under Chapter 11 of the U.S. Bankruptcy Code (the “Filing”), a review of publicly available information and in accordance with Listing Rules 5101, 5110(b) and IM-5101-1, it determined that the Company’s securities will be delisted from Nasdaq. | d314723d8k.htm |
| 2022-06-02 | 8-K | 2022-05-26 | 1.02 Termination of a Material Definitive Agreement; 1.03 Bankruptcy or Receivership; 8.01 Other Events | 1.02 On May 26, 2022, Zosano Pharma Corporation, a Delaware corporation (the “Company”), repaid all amounts due and owing by the Company to Trinity Capital Inc. (the “Lessor”) pursuant to the Master Lease Agreement dated as of September 25, 2018 by and between Trinity Capital Funding III, L.P. as predecessor in interest to the Lessor and the Company, as amended (“Lease Agreement”). 1.03 On June 1, 2022, the Company (the “Debtor”) filed a voluntary petition for relief under chapter 11 of title 11 (“Chapter 11”) of the United States Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), thereby commencing a Chapter 11 case for the Debtor. 8.01 On June 2, 2022, the Company issued a press release announcing the filing of the Chapter 11 case. | d298742d8k.htm |
| 2022-05-18 | 8-K | 2022-05-16 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 16, 2022, Donald J. Kellerman, Vice President, Clinical Development and Medical Affairs of Zosano Pharma Corporation (the “Company”), informed the Company of his decision to retire, effective June 1, 2022. | d252044d8k.htm |
| 2022-05-13 | 8-K | 2022-05-10 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.02 On May 13, 2022, Zosano Pharma Corporation (the “Company”) issued a press release titled “Zosano Pharma Reports First Quarter 2022 Financial Results.” The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. 5.02 On May 10, 2022, Joseph “Jay” P. Hagan tendered his resignation as a director of the board of directors (the “Board”) of the Company and as chairperson of the audit committee of the Board, effective immediately. | zsan-20220510.htm |
| 2022-05-05 | 8-K | 2022-05-03 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 3, 2022, Steven A. Elms tendered his resignation as a director of the board of directors (the “Board”) of Zosano Pharma Corporation (the “Company”) and as a member of the compensation and nominating and corporate governance committees of the Board, effective immediately. | d280596d8k.htm |
| 2022-04-29 | 8-K | 2022-04-29 | 8.01 Other Events | 8.01 On April 29, 2022, Zosano Pharma Corporation issued a press release providing a corporate update. | d638762d8k.htm |
| 2022-04-11 | 8-K | 2022-04-08 | 3.03 Material Modification to Rights of Security Holders; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 8.01 Other Events | 3.03 To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated herein by reference. 5.03 On April 11, 2022, Zosano Pharma Corporation (the “Company”) effected a 1-for-35 reverse stock split of its common stock (the “Reverse Stock Split”). 5.07 On April 8, 2022, the Company held a special meeting of stockholders (the “Special Meeting”). 8.01 On April 11, 2022, the Company issued a press release announcing the Reverse Stock Split. | d329060d8k.htm |
| 2022-03-17 | 8-K | 2022-03-17 | 2.02 Results of Operations and Financial Condition | 2.02 On March 17, 2022, Zosano Pharma Corporation issued a press release titled “Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results.” The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. | zsan-20220317.htm |
| 2022-02-18 | 8-K | 2022-02-17 | 8.01 Other Events | 8.01 On February 17, 2022, Zosano Pharma Corporation (“Zosano” or the “Company”) received a response letter from the U.S. Food and Drug Administration (“FDA”) with regard to the Company’s January 18, 2022 resubmission of the 505(b)(2) New Drug Application for M207 (zolmitriptan microneedle system) (“M207 NDA”). | d290090d8k.htm |
| 2022-02-09 | 8-K | 2022-02-08 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On February 8, 2022, Zosano Pharma Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Maxim Group LLC (“Maxim”) related to the public offering by the Company of 51,250,000 units (“Units”), each consisting of one share of common stock, par value $0.0001 per share, of the Company (the “Common Stock”) and one Series F Common Stock Purchase Warrant (“Series F Warrant”) to purchase one share of Common Stock, at a public offering price of $0.30 per Unit ($0.29 per share of Common Stock and $0.01 per Warrant). 8.01 Currently, the Company has approximately $7.6 million in cash and cash equivalents. | d484151d8k.htm |
| 2022-01-31 | 8-K | 2022-01-28 | 8.01 Other Events | 8.01 On January 28, 2022, Zosano Pharma Corporation posted an updated corporate presentation to its website. | zsan-20220128.htm |
| 2022-01-24 | 8-K | 2022-01-18 | 8.01 Other Events | 8.01 On January 18, 2022, Zosano Pharma Corporation (“Zosano” or the “Company”) resubmitted its M207 (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) following the Complete Response Letter received on October 20, 2020. | zsan-20220118.htm |
| 2022-01-05 | 8-K | 2022-01-05 | 8.01 Other Events | 8.01 On January 5, 2022, Zosano Pharma Corporation (the "Company") announced the publication of Phase 1 clinical trial data in an article titled, “Immunogenicity and Safety of Inactivated Influenza Split-Virion Vaccine Administered via a Transdermal Microneedle System” in the Journal of Vaccines and Immunology. | zsan-20220105.htm |